Weiyue Lu, Ph.D.,Professor of Pharmaceutics in School of pharmacy, Fudan University. He graduated from Shanghai First Medical College (Now School of Pharmacy, Fudan University) in 1982 and got Ph.D. degree in Pharmaceutics from Shanghai Institute of Pharmaceutical Industry. Now he is the academic leader of the national key discipline (Pharmaceutics, Fudan University), the principle investigator of 973 project, State Council Expert for Special Allowance, the director of the Pharmaceutics Committee of Chinese Pharmaceutical Association (CPA), the associate director of the Nanomedicine Committee of CPA and the supervisor to two National 100 Excellent Ph.D. Thesis Prizes. He is interested in the field of targeted drug delivery in which he has 140 research papers, 23 licensed patents and two new drug certificates.
Tumor, brain & lymphatic targeting strategy; Drug delivery
Education
1978.09-1982.07 B.S. in Medicinal Chemistry, Department of Pharmacy, Shanghai First Medical College.
2005.09-2013.12 Ph.D. in Pharmaceutics, Shanghai Institute of Pharmaceutical Industry (Supervisor: Academician Huimin Hou).
Professional Experiences
Since 1982, he successively worked as Assistant Professor, Associate Professor and Professor in Department of Physical Chemistry, School of Pharmacy, Shanghai First Medical College, Department of Targeting Pharmaceuticals, Institute of Pharmacy, Shanghai First Medical College and now School of Pharmacy, Fudan University.
He is Professor (secondary grade), Distinguished Professor, Expert obtaining the special allowance of State Council and the Leader of State Key Discipline Pharmaceutics (Fudan University). He worked as PI of the “Technological platform for novel formulation and novel drug delivery systems” supported by National Science and Technology Major Project in the 11th Five-Year Plan and the 12th Five-Year Plan and the 973 program “Novel nanomedicine for brain tumor therapy”. He has worked as the first director of Key laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, China. He has worked as the PI of 21 national, provincial and ministerial research projects, published over 120 SCI-indexed papers and got 23 patents licensed. He has 2 national new drug certificate and 1 new drug clinical approval.
Teaching Activities
1982.09-1995.01：“Physical Chemistry” for undergraduates;
1995.02-2000.01：“Theory and Techniques of Surface Films” for graduates;
2000.02-2017.07：“Physical Chemistry” for undergraduates, “Physical Chemistry” for graduates, “Targeting Drug Delivery Systems” for undergraduates, “Targeting Drug Delivery Systems” for graduates and “Frontiers of Pharmaceutics” for doctoral graduates.
1995.03-present: Has supervised 18 master graduates, 25 Ph.D. graduates (including 4 joint-instruction) and 9 post-doctoral fellowships (including 3 joint-instruction).
Grants & Projects
As PI
1. National Basic Research Program of China (973 Program): “Novel nanomedicine for brain tumor therapy” (2013CB932500).
2. National Science and Technology Major Project: “Platform of novel formulation and novel drug delivery systems” (2009ZX09310-006).
3. National High Technology Research and Development Program of China (863 program): “Investigation on tumor-targeted smart material folate-PEG and related nano- drug delivery system” (2006AA03Z325).
4. NSFC (8): “Long-circulating biomimic nanodrug delivery systems” (General, 81773657), “Delivery mechanism of biomacromolecule drug delivery systems with high efficiency” (Major, 81690263), “Structural optimization and in vivo delivery of anti-cancer stapled D-peptides” (General, 81473149), “Multi-target targeted liposome joint administration system for glioma therapy” (General, 81273458), “Lyp-1-mediated lymphatic metastasis-targeted liposome drug delivery systems” (General, 81072593), “Construction and mechanism investigation on liposome drug delivery systems for local administration with high efficiency and low toxicity” (General, 30672545), “Studies on stealth liposomes modified with ch-TNT” (General, 30271550) and “Folic conjugates as targeting carriers of radionuclide and anti-tumor agents” (General, 39670859).
5. Doctoral Science Foundation of Ministry of Education of China (3): “Studies on liposomal drug delivery systems based on triple targeting strategy for prevention and treatment of tumor metastasis” (20110071130011), “Studies on antitumor drug carriers with active lymph targeting effect” (20030246050) and “Studies on folate conjugates as tumor cell targeting drug carriers” (9506183).
6. Funds from Shanghai (7): “Drug delivery strategy of glioma whole-process trageting” (Major Projects of Shanghai Education Committee, 2017-01-07-00-07-E00052), “Design and targeted delivery of novel anti-tumor polypeptide drug” (Shanghai International Collaboration Fund, 11430707900), “Folate-PEG-PE nano- micelles for tumor cell active targeting”(Shanghai Nano Program, 0953nm03300), “New drug carrier for insoluble drugs”(Shanghai Scientific and Technological Key Project 074319117); “Investigation on liposome drug delivery systems for local administration with high efficiency and low toxicity” (Shanghai Nano Program, 0652nm011); “Preclinical studies on folate-polysaccharide complexes for tumor targeting mediated by folate receptors” (Shanghai Modern Biological and Drug Development Foundation, 024319230) and “Delayed release capsules containing mucoadhesive microspheres of amoxicillin” (Shanghai Modern Biological and Drug Development Foundation , 20004319218).
As participant
1. National Basic Research Program of China (973 Program) (2): “Applicational basic research on targeted nano drug delivery system” (2007CB935800) and “Applicational basic research on new nanotechnology-based formulation for improving tumor therapy” (2010CB934000).
2. National Science and Technology Major Project (as the head of Fudan University part): “Construction of GLP-conforming Technological platform for novel formulation and novel drug delivery systems” (2012ZX09304004).
3. National High Technology Research and Development Program of China (863 program) (as the deputy head): “Novel controlled release carriers for proteins” (2001AA215451+2004AA215170).
Awards & Honors
Since 2000, He has won "Prize for Excellent Teacher" funded by Baosteel Fellowship, "Life Science Award" funded by Meiji Dairies Corp.(Shanghai), "Gold Medal of Xu Guang Qi Science and Technology Medal”, “Pu Kang Fellowship” of Fudan University, Excellent graduate supervisor of Fudan University, Supervisor of two “National 100 Excellent Doctoral Dissertation Award”, "Yu-Cai Prize" of Shanghai, Second Prize for Scientific and Technological Progress of Education Ministry (PI), Second Prize for Science and Technology of Chinese Pharmaceutical Association (PI), Second Prize of Shanghai Science and Technology (PI) and Second Prize of Shanghai Pharmaceutical Science and Technology (PI).
Memberships
Now he is the executive director of Chinese Pharmaceutical Association (CPA), the member of the Academic Committee of CPA, the director of the Pharmaceutics Committee of CPA, the associate director of the Nanomedicine Committee of CPA, the member of the Standing Committee of the Nano-oncology Committee of Chinese Anti-Cancer Association, the member of the Standing Committee of the Nano Biology and Medicine Committee of Chinese Association of Biomedical Engineering, the honorary director of Pharmaceutics Committee of Shanghai Pharmaceutical Association, the member of Academic Committee of Fudan University, the member of Academic Committee of Fudan University Shanghai Medical College, the member of the National Instruction Committee for Graduate Education of Pharmaceutical Professional Degree and the member of the 5th discipline evaluation committee of Shanghai Academic Degree Committee.
Selected Publications
1. A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J Control Release 2017, 264:102-111
2. D-retro-enantiomer of Quorum Sensing Peptides-Modified Polymeric Micelles for Brain Tumor Targeted Drug Delivery. ACS Appl Mater Interfaces 2017, 9(31):25672-25682
3. Stapled RGD Peptide Enables Glioma-Targeted Drug Delivery by Overcoming Multiple Barriers. ACS Appl Mater Interfaces 2017, 9(21):17745-17756
4. GRP78 enabled micelle-based glioma targeted drug delivery. J Control Release 2017, 255:120-131
5. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery. J Control Release 2017, 255:132-141
6. A Stabilized Peptide Ligand for Multifunctional Glioma Targeted Drug Delivery. J Control Release 2016, 243:86-98
7. Liposome-based Systemic Glioma-Targeted Drug Delivery Enabled by All-D Peptides. ACS Appl Mater Interfaces 2016, 8(44):29977-29985
8. Toxins and derivatives in molecular pharmaceutics: Drug delivery and targeted therapy. Adv Drug Deliv Rev 2015, 90:101-8
9. A D-Peptide Ligand of Nicotine Acetylcholine Receptors for Brain-Targeted Drug Delivery. Angew Chem Int Ed 2015, 54:3023-7
10. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. J Control Release 2015, 218:29-35
